IMPRESS: IMPlementation of Evidence Based Facility and Community Interventions to Reduce the Treatment Gap for depRESSion

Sponsor
Sangath (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05890222
Collaborator
London School of Hygiene and Tropical Medicine (Other), Harvard Medical School (HMS and HSDM) (Other), Centre for Addiction and Mental Health (Other)
1,680
1
2
18
93.1

Study Details

Study Description

Brief Summary

The goal of this Hybrid Type 2 Implementation-Effectiveness Cluster Randomised Controlled Trial is to reduce the treatment gap for depression through the integrated implementation of interventions in facility and community platforms, in Goa, India. The primary question is to examine whether a community intervention ("Community Model") enhances the demand for, and improves the outcomes of, an evidence-based, brief psychological treatment for depression delivered by non-specialist health workers in primary health care facilities ("Facility Model"). Participants in the Facility Model arm will receive only a psychosocial intervention for depression (the Healthy Activity Program - HAP) while participants in the Community Model will receive both the HAP and the community intervention. We will compare the Facility Model and the Community Model to assess if the latter is superior in increasing the demand for depression treatment in primary care, increasing uptake of treatment by people with depression, increasing treatment completion rates, and reducing the severity of depression.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Community Intervention
  • Behavioral: Healthy Activity Program (HAP)
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
1680 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
IMPlementation of Evidence Based Facility and Community Interventions to Reduce the Treatment Gap for depRESSion
Anticipated Study Start Date :
Jul 1, 2023
Anticipated Primary Completion Date :
Sep 30, 2024
Anticipated Study Completion Date :
Dec 31, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Community Model

In addition to the facility model, village clusters in this arm will receive community intervention strategies delivered by community volunteers.

Behavioral: Community Intervention
Community intervention strategies will be delivered by community volunteers (called Sangathis - which means companion in Konkani, one of the local languages) to i) enhance demand for the HAP treatment and ii) promote engagement with, and completion of, the HAP treatment. The community intervention is co-produced with local community members and includes strategies such as activities to increase awareness about depression (community meetings, street plays and health camps), and dissemination of psycho-educational materials (i.e., leaflets and posters), identify people with possible depression in the community, and facilitate access to HAP in the health centres. Additionally, the Sangathis will coordinate continuing care of people receiving HAP, through home visits to encourage behavioural activation, homework completion and following up with the counsellor, and engaging family members to support the patient in achieving treatment goals.

Behavioral: Healthy Activity Program (HAP)
HAP includes the following strategies: psychoeducation, behavioural assessment, activity monitoring, activity structuring and scheduling, activation of social networks, and problem-solving. HAP will be delivered in an individual format. It entails three phases of treatment, delivered over six to eight sessions, each lasting up to 40 minutes, with the sessions being at weekly intervals. Sessions will be delivered face-to-face, at the health centre where the counsellors already work.

Active Comparator: Facility Model

The HAP, a manualized and evidence-based psychological treatment based on behavioural activation, will be delivered by existing healthcare workers (called counsellors from here onwards) within the health centres who will be trained to deliver the HAP.

Behavioral: Healthy Activity Program (HAP)
HAP includes the following strategies: psychoeducation, behavioural assessment, activity monitoring, activity structuring and scheduling, activation of social networks, and problem-solving. HAP will be delivered in an individual format. It entails three phases of treatment, delivered over six to eight sessions, each lasting up to 40 minutes, with the sessions being at weekly intervals. Sessions will be delivered face-to-face, at the health centre where the counsellors already work.

Outcome Measures

Primary Outcome Measures

  1. Contact coverage [Three months post recruitment]

    Patient Health Questionnaire 9 items (PHQ-9) score >4. The minimum score is 0 and maximum score is 27; with higher scores indicating greater severity of depression.

  2. Effectiveness coverage [Three months post recruitment]

    Mean Patient Health Questionnaire 9 items (PHQ-9 score). The minimum score is 0 and maximum score is 27; with higher scores indicating greater severity of depression.

Secondary Outcome Measures

  1. Sustained effectiveness [Six months post recruitment]

    Mean Patient Health Questionnaire 9 items (PHQ-9 score). The minimum score is 0 and maximum score is 27; with higher scores indicating greater severity of depression.

  2. Remission [Three months post recruitment]

    Patient Health Questionnaire 9 items (PHQ-9 score) score <10. . The minimum score is 0 and maximum score is 27; with higher scores indicating greater severity of depression.

  3. Remission [Six months post recruitment]

    Patient Health Questionnaire 9 items (PHQ-9 score) score <10. . The minimum score is 0 and maximum score is 27; with higher scores indicating greater severity of depression.

  4. Response to treatment [Three months post recruitment]

    >50% reduction in Patient Health Questionnaire 9 items (PHQ-9 score) score. The minimum score is 0 and maximum score is 27; with higher scores indicating greater severity of depression.

  5. Response to treatment [Six months post recruitment]

    >50% reduction in Patient Health Questionnaire 9 items (PHQ-9 score) score. The minimum score is 0 and maximum score is 27; with higher scores indicating greater severity of depression.

  6. Client Service Receipt Inventory [Baseline, 3- and 6- months post recruitment]

    Out-of-pocket costs for receiving care and the related non-medical costs

  7. WHO Disability Assessment Schedule (WHODAS 2.0) [3- and 6- months post recruitment]

    Standardized disability scores used to estimate Quality Adjusted Life Years (QALYs). The 12-item WHODAS 2.0 score ranges from 12 to 60, where higher scores indicate higher disability or loss of function.

  8. Depression awareness [Baseline, 6 and 12 months of implementation]

    Awareness about depression. This will be a bespoke tool developed for our trial and will have questions to assess awareness related to depression based on the information disseminated in our community intervention and higher scores will indicate greater awareness.

  9. Perceived social support [Baseline, 3- and 6- months post recruitment]

    Perception of social support received. This will be a bespoke tool developed for our trial and will have questions to assess perceived support related to support provided by community volunteers in our community intervention and higher scores will indicate greater awareness.

  10. Treatment completion [Across 12 months of implementation]

    Met treatment goals or completed the maximum number of sessions or were referred to mental health specialists

  11. Behavioral activation [Baseline, 3- and 6- months post recruitment.]

    Level of behavioral activation measured using PREMIUM Abbreviated Activation Scale. This is a five-item scale, originally developed based on the Behavioural Activation for Depression Scale. It includes five self-reported indicators and the total score can range from 0 to 25. Higher scores indicate greater level of behavioural activation such as engagement with a variety of activities, and associated pleasure and mastery.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No

(A) Contact Coverage Outcome

Inclusion Criteria

  • Adults (>18 years)

  • Residing in the clusters included in the trial

  • Speak English or one of the local languages (Konkani, Marathi, Hindi)

Exclusion Criteria

  • Patients with significant speech, hearing, or language impairment that interferes with completion of the screening and/or receipt of psychosocial intervention

  • Patients who present to the health centre for emergency medical attention

  • Patients with active psychotic symptoms

(B) Effectiveness Coverage Outcome

Inclusion Criteria

  • Adults (>18 years);

  • Residing in the clusters included in the trial

  • Speak English or one of the local languages (Konkani, Marathi, Hindi).

  • Screen positive for moderately severe or severe depression (total score >15) on the Patient Health Questionnaire-9 items (PHQ-9)

  • Intend to reside in the trial clusters for at least 3 months (to enhance the likelihood of completion of treatment)

Exclusion Criteria

  • Patients with significant speech, hearing, or language impairment that interferes with completion of the screening and/or receipt of psychosocial intervention

  • Patients who present to the health centre for emergency medical attention

  • Patients with active psychotic symptoms

  • Patients who do not have access to a mobile phone as that will be needed for communicating with the counsellors and Sangathis, for example, to follow-up if the patient misses an appointment.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Sangath Goa India

Sponsors and Collaborators

  • Sangath
  • London School of Hygiene and Tropical Medicine
  • Harvard Medical School (HMS and HSDM)
  • Centre for Addiction and Mental Health

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Sangath
ClinicalTrials.gov Identifier:
NCT05890222
Other Study ID Numbers:
  • SAN_IMPRESS_2023
First Posted:
Jun 6, 2023
Last Update Posted:
Jun 6, 2023
Last Verified:
May 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 6, 2023